Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Liyu, Jiang"'
Autor:
Dan Luo, Yiran Liang, Yajie Wang, Fangzhou Ye, Yuhan Jin, Yaming Li, Dianwen Han, Zekun Wang, Bing Chen, Wenjing Zhao, Lijuan Wang, Xi Chen, Liyu Jiang, Qifeng Yang
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-20 (2023)
Abstract Background Triple-negative breast cancer (TNBC) is a subtype of breast cancer with higher aggressiveness and poorer outcomes. Recently, long non-coding RNAs (lncRNAs) have become the crucial gene regulators in the progression of human cancer
Externí odkaz:
https://doaj.org/article/7327a182b2c044528901ba7944b4436f
Publikováno v:
Fractal and Fractional, Vol 8, Iss 3, p 157 (2024)
Car-like mobile robots (CLMRs) are extensively utilized in various intricate scenarios owing to their exceptional maneuverability, stability, and adaptability, in which path planning is an important technical basis for their autonomous navigation. Ho
Externí odkaz:
https://doaj.org/article/85513c4e0bb94edabd35db15fe4e21eb
Autor:
Shishuai Wen, Yiran Liang, Xiaoli Kong, Baofeng Liu, Tingting Ma, Yeqing Zhou, Liyu Jiang, Xiaoyan Li, Qifeng Yang
Publikováno v:
BMC Surgery, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background In light of the extensive application of sentinel lymph node biopsy (SLNB) in clinically node-negative breast cancer patients and the recently investigated failure of SLNB after lumpectomy, it has become important to explore metho
Externí odkaz:
https://doaj.org/article/a0300bfdb3204bb48224a701d2372021
Publikováno v:
Sensors, Vol 23, Iss 5, p 2501 (2023)
Mobile robots are widely employed in various fields to perform autonomous tasks. In dynamic scenarios, localization fluctuations are unavoidable and obvious. However, common controllers do not consider the impact of localization fluctuations, resulti
Externí odkaz:
https://doaj.org/article/2a57d5e768c14a97acfcabe0a4b994b6
Autor:
Yeqing Zhou, Yiran Liang, Jianshu Zhang, Yang Feng, Xiaoyan Li, Xiaoli Kong, Tingting Ma, Liyu Jiang, Qifeng Yang
Publikováno v:
Frontiers in Surgery, Vol 8 (2021)
Background: The resection of nonpalpable breast lesions (NPBLs) largely depends on the preoperative localization technology. Although several techniques have been used for the guidance of NPBL resection, more comfortable and effective methods are nee
Externí odkaz:
https://doaj.org/article/c17874cd2d8949f29e545e0671138c71
Publikováno v:
Cellular Physiology and Biochemistry, Vol 44, Iss 2, Pp 581-593 (2017)
Background/Aims: Increasing evidence indicates that Huaier extract has promising therapeutic effects against cancer. However, the mechanisms that underlie its anti-tumor effects remain unclear. In recent years, various studies have shown that long no
Externí odkaz:
https://doaj.org/article/9a442545fd5c4016a0253145721f2186
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Abstract Endocrine therapy is one of the main treatments for breast cancer patients in the early stages. Tamoxifen and fulvestrant are the major drugs of endocrine therapy for breast cancer patients. However, acquired drug resistance often caused tre
Externí odkaz:
https://doaj.org/article/eab71cee0273459bbcb763ec3ec32fda
Publikováno v:
Cellular Physiology and Biochemistry, Vol 33, Iss 1, Pp 165-172 (2014)
Background: Calcium-sensing receptor (CaSR) is a typical G protein coupled receptor. The rs17251221 SNP is located in an intron of the CaSR gene, and the G allele is considered a gain of function mutation. Previous studies revealed that rs17251221 po
Externí odkaz:
https://doaj.org/article/18a602176c1d419d8dfff2f63608c778
Publikováno v:
Expert Review of Clinical Pharmacology. 14:445-456
Introduction: Nilotinib is a second-generation tyrosine kinase inhibitor (TKI) targeting BCR/ABL, which is used for the first-line treatment of newly diagnosed chronic myeloid leukemia (CML) patients and the second-line treatment of most CML patients
Autor:
Liyu Jiang, Yan Zeng, Leilei Ai, Hao Yan, Xiaochun Yang, Peihua Luo, Bo Yang, Zhifei Xu, Qiaojun He
Publikováno v:
Biochemical pharmacology. 201
The application of lapatinib, a widely used dual inhibitor of human epidermal growth factor receptor 1 (EGFR/ERBB1) and 2 (HER2/ERBB2), has been seriously limited due to cutaneous toxicity. However, the specific mechanism of lapatinib-induced cutaneo